文献速递炎症性肠病

TNF拮抗剂治疗难治性溃疡性直肠炎的疗效

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-06-13

这项法国和比利时的全国性回顾性队列研究纳入104例难治性活动性溃疡性直肠炎(UP)患者,接受至少一次抗TNF治疗。77%患者获得临床应答,50%达到临床缓解,60%内镜评估者实现黏膜愈合。1年和2年持续临床缓解累积概率分别为87.6%±3.4%和74.7%±4.8%。

要点

  • 抗TNF治疗难治性UP:77%临床应答,50%临床缓解
  • 随访内镜评估者中60%达到黏膜愈合
  • 肠外表现及局部激素或5-ASA治疗与未缓解相关

核心结论

  • 在104例难治性UP的回顾性研究中,抗TNF治疗使50%患者达到临床缓解,60%内镜评估者达到黏膜愈合,约三分之二患者在2年时仍在接受抗TNF治疗。

研究设计与样本

  • 法国15个中心及比利时1个中心的全国性回顾性队列研究(GETAID队列),纳入104例连续的活动性UP且常规治疗难治的患者,2006年10月至2017年2月接受至少1次抗TNF(英夫利西单抗、阿达木单抗、戈利木单抗)治疗,中位随访24个月(IQR 13-51个月)。

主要发现

  • 总体80例(77%)患者对抗TNF治疗有临床应答,52例(50%)达到临床缓解。
  • 肠外表现(OR 0.24;95%CI 0.08-0.7)、正在使用局部激素(OR 0.14;95%CI 0.03-0.73)和正在使用局部5-氨基水杨酸(OR 0.21;95%CI 0.07-0.62)与未达到临床缓解显著相关。
  • 随访期间接受内镜评估的63例患者中38例(60%)达到黏膜愈合。
  • 总体人群(n=104)持续临床缓解的累积概率为1年87.6%±3.4%、2年74.7%±4.8%。

关键数值与推荐

  • 临床应答定义为UC相关症状显著改善,临床缓解定义为UC相关症状完全消失,均由治疗医生判定。
  • 主要结局为UP对抗TNF治疗的临床应答。
  • 约三分之二的患者在2年时仍在接受抗TNF治疗。

临床怎么用

  • 对于常规治疗难治的溃疡性直肠炎患者,抗TNF治疗可使约半数达到临床缓解、约六成内镜评估者达到黏膜愈合。
  • 合并肠外表现、正在使用局部激素或局部5-氨基水杨酸的患者达到临床缓解的可能性较低。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. METHODS: We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. Clinical response was defined as significant improvement in UC-related symptoms, and remission as complete disappearance of UC-related symptoms, each determined by treating physicians. We collected demographic, clinical, and treatment data. The median duration of follow-up was 24 months (interquartile range, 13-51 months). The primary outcome was clinical response of UP to anti-TNF treatment. RESULTS: Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08-0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03-0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07-0.62) were significantly associated with the absence of clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during follow up had mucosal healing. Among the overall population (n = 104), the cumulative probabilities of sustained clinical remission were 87.6% ± 3.4% at 1 year and 74.7% ± 4.8% at 2 years. CONCLUSIONS: In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the patients were still receiving anti-TNF therapy at 2 years.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pineton de Chambrun G, Amiot A, Bouguen G, et al. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2019. PMID: 31202984. doi:10.1016/j.cgh.2019.05.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。